Fate Therapeutics Analyst Price Targets

Fate Therapeutics Inc

FATENASDAQ

Trade with Public

$1.87

0.084.47%

最終更新: Oct 19, 2:07 PM

$1.78

-0.01-0.56%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Fate Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fate Therapeutics (FATE).

Price Target Range — 10 Quarters

Analyst Consensus — 11 Analysts

6Buy

4Hold

1Sell

Consensus RatingBuy# Analysts11Avg. Consensus PT$6Upside to Avg. PT+215.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 14, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$6→$8
Aug 14, 2026	Wells Fargo	Yanan Zhu	PT Raise	Equal-Weight	$3→$4
Aug 14, 2026	Wedbush	Martin Fan	Maintained	Outperform	$7
Jun 8, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7
May 4, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$5→$7
Oct 31, 2025	HC Wainwright & Co.	Robert Burns	Upgrade	Neutral→Buy	$5
Oct 27, 2025	Wedbush	David Nierengarten	Upgrade	Neutral→Outperform	$5→$7
Oct 27, 2025	Needham	Gil Blum	Maintained	Hold	—
Aug 13, 2025	Wells Fargo	Yanan Zhu	PT Cut	Equal-Weight	$4→$3
Jun 12, 2025	Needham	Gil Blum	Maintained	Hold	—
May 14, 2025	Barclays	Peter Lawson	PT Cut	Overweight	$10→$2
May 14, 2025	Baird	Jack Allen	PT Cut	Neutral	$5→$4
May 14, 2025	Needham	Gil Blum	Maintained	Hold	—
Mar 6, 2025	Stifel	Benjamin Burnett	PT Cut	Hold	$5→$3
Mar 6, 2025	Wedbush	David Nierengarten	Maintained	Neutral	$5
Mar 6, 2025	Wells Fargo	Yanan Zhu	PT Cut	Equal-Weight	$5→$4
Mar 6, 2025	Needham	Gil Blum	Maintained	Hold	—
Nov 19, 2024	Needham	Gil Blum	Maintained	Hold	—
Nov 13, 2024	Needham	Gil Blum	Maintained	Hold	—
Aug 22, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$5

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $5 to $7.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Buy and maintains the price target from $5 to $5.

Benzinga Newsdesk

Fate Therapeutics Inc

Fate Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

PRO
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

PRO
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

PRO
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

ニュース

パートナーシップ

ベンジンガ・グローバル

Fate Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

PRO
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

PRO
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

PRO
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

People Also Watch

People Also Watch

Fate Therapeutics Inc

Fate Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

PROWells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

PROWedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

PROHC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

PROHC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

PROHC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

ニュース

パートナーシップ

ベンジンガ・グローバル

Fate Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

PROWells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

PROWedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

PROHC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

PROHC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

PROHC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

People Also Watch

People Also Watch

PRO
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

PRO
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

PRO
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

PRO
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

PRO
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

PRO
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

PRO
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

PRO
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5